scispace - formally typeset
Search or ask a question

Showing papers by "Mohsen Naghavi published in 2018"


Journal ArticleDOI
Gregory A. Roth1, Gregory A. Roth2, Degu Abate3, Kalkidan Hassen Abate4  +1025 moreInstitutions (333)
TL;DR: Non-communicable diseases comprised the greatest fraction of deaths, contributing to 73·4% (95% uncertainty interval [UI] 72·5–74·1) of total deaths in 2017, while communicable, maternal, neonatal, and nutritional causes accounted for 18·6% (17·9–19·6), and injuries 8·0% (7·7–8·2).

5,211 citations


Journal ArticleDOI
TL;DR: In this paper, the authors assess the burden of 29 cancer groups over time to provide a framework for policy discussion, resource allocation, and research focus, and evaluate cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs) for 195 countries and territories by age and sex using the Global Burden of Disease study estimation methods.
Abstract: Importance The increasing burden due to cancer and other noncommunicable diseases poses a threat to human development, which has resulted in global political commitments reflected in the Sustainable Development Goals as well as the World Health Organization (WHO) Global Action Plan on Non-Communicable Diseases. To determine if these commitments have resulted in improved cancer control, quantitative assessments of the cancer burden are required. Objective To assess the burden for 29 cancer groups over time to provide a framework for policy discussion, resource allocation, and research focus. Evidence Review Cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs) were evaluated for 195 countries and territories by age and sex using the Global Burden of Disease study estimation methods. Levels and trends were analyzed over time, as well as by the Sociodemographic Index (SDI). Changes in incident cases were categorized by changes due to epidemiological vs demographic transition. Findings In 2016, there were 17.2 million cancer cases worldwide and 8.9 million deaths. Cancer cases increased by 28% between 2006 and 2016. The smallest increase was seen in high SDI countries. Globally, population aging contributed 17%; population growth, 12%; and changes in age-specific rates, −1% to this change. The most common incident cancer globally for men was prostate cancer (1.4 million cases). The leading cause of cancer deaths and DALYs was tracheal, bronchus, and lung cancer (1.2 million deaths and 25.4 million DALYs). For women, the most common incident cancer and the leading cause of cancer deaths and DALYs was breast cancer (1.7 million incident cases, 535 000 deaths, and 14.9 million DALYs). In 2016, cancer caused 213.2 million DALYs globally for both sexes combined. Between 2006 and 2016, the average annual age-standardized incidence rates for all cancers combined increased in 130 of 195 countries or territories, and the average annual age-standardized death rates decreased within that timeframe in 143 of 195 countries or territories. Conclusions and Relevance Large disparities exist between countries in cancer incidence, deaths, and associated disability. Scaling up cancer prevention and ensuring universal access to cancer care are required for health equity and to fulfill the global commitments for noncommunicable disease and cancer control.

4,621 citations


Journal ArticleDOI
Jeffrey D. Stanaway1, Ashkan Afshin1, Emmanuela Gakidou1, Stephen S Lim1  +1050 moreInstitutions (346)
TL;DR: This study estimated levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs) by age group, sex, year, and location for 84 behavioural, environmental and occupational, and metabolic risks or groups of risks from 1990 to 2017 and explored the relationship between development and risk exposure.

2,910 citations


Journal ArticleDOI
Max Griswold1, Nancy Fullman1, Caitlin Hawley1, Nicholas Arian1  +515 moreInstitutions (37)
TL;DR: It is found that the risk of all-cause mortality, and of cancers specifically, rises with increasing levels of consumption, and the level of consumption that minimises health loss is zero.

1,831 citations


Journal ArticleDOI
TL;DR: Over the past generation, the global burden of Parkinson's disease has more than doubled as a result of increasing numbers of older people, with potential contributions from longer disease duration and environmental factors.
Abstract: Summary Background Neurological disorders are now the leading source of disability globally, and ageing is increasing the burden of neurodegenerative disorders, including Parkinson's disease. We aimed to determine the global burden of Parkinson's disease between 1990 and 2016 to identify trends and to enable appropriate public health, medical, and scientific responses. Methods Through a systematic analysis of epidemiological studies, we estimated global, regional, and country-specific prevalence and years of life lived with disability for Parkinson's disease from 1990 to 2016. We estimated the proportion of mild, moderate, and severe Parkinson's disease on the basis of studies that used the Hoehn and Yahr scale and assigned disability weights to each level. We jointly modelled prevalence and excess mortality risk in a natural history model to derive estimates of deaths due to Parkinson's disease. Death counts were multiplied by values from the Global Burden of Disease study's standard life expectancy to compute years of life lost. Disability-adjusted life-years (DALYs) were computed as the sum of years lived with disability and years of life lost. We also analysed results based on the Socio-demographic Index, a compound measure of income per capita, education, and fertility. Findings In 2016, 6·1 million (95% uncertainty interval [UI] 5·0–7·3) individuals had Parkinson's disease globally, compared with 2·5 million (2·0–3·0) in 1990. This increase was not solely due to increasing numbers of older people, because age-standardised prevalence rates increased by 21·7% (95% UI 18·1–25·3) over the same period (compared with an increase of 74·3%, 95% UI 69·2–79·6, for crude prevalence rates). Parkinson's disease caused 3·2 million (95% UI 2·6–4·0) DALYs and 211 296 deaths (95% UI 167 771–265 160) in 2016. The male-to-female ratios of age-standardised prevalence rates were similar in 2016 (1·40, 95% UI 1·36–1·43) and 1990 (1·37, 1·34–1·40). From 1990 to 2016, age-standardised prevalence, DALY rates, and death rates increased for all global burden of disease regions except for southern Latin America, eastern Europe, and Oceania. In addition, age-standardised DALY rates generally increased across the Socio-demographic Index. Interpretation Over the past generation, the global burden of Parkinson's disease has more than doubled as a result of increasing numbers of older people, with potential contributions from longer disease duration and environmental factors. Demographic and potentially other factors are poised to increase the future burden of Parkinson's disease substantially. Funding Bill & Melinda Gates Foundation.

1,388 citations


Journal ArticleDOI
TL;DR: The findings show substantial progress in the reduction of lower respiratory infection burden, but this progress has not been equal across locations, has been driven by decreases in several primary risk factors, and might require more effort among elderly adults.
Abstract: Summary Background Lower respiratory infections are a leading cause of morbidity and mortality around the world The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study 2016, provides an up-to-date analysis of the burden of lower respiratory infections in 195 countries This study assesses cases, deaths, and aetiologies spanning the past 26 years and shows how the burden of lower respiratory infection has changed in people of all ages Methods We used three separate modelling strategies for lower respiratory infections in GBD 2016: a Bayesian hierarchical ensemble modelling platform (Cause of Death Ensemble model), which uses vital registration, verbal autopsy data, and surveillance system data to predict mortality due to lower respiratory infections; a compartmental meta-regression tool (DisMod-MR), which uses scientific literature, population representative surveys, and health-care data to predict incidence, prevalence, and mortality; and modelling of counterfactual estimates of the population attributable fraction of lower respiratory infection episodes due to Streptococcus pneumoniae, Haemophilus influenzae type b, influenza, and respiratory syncytial virus We calculated each modelled estimate for each age, sex, year, and location We modelled the exposure level in a population for a given risk factor using DisMod-MR and a spatio-temporal Gaussian process regression, and assessed the effectiveness of targeted interventions for each risk factor in children younger than 5 years We also did a decomposition analysis of the change in LRI deaths from 2000–16 using the risk factors associated with LRI in GBD 2016 Findings In 2016, lower respiratory infections caused 652 572 deaths (95% uncertainty interval [UI] 586 475–720 612) in children younger than 5 years (under-5s), 1 080 958 deaths (943 749–1 170 638) in adults older than 70 years, and 2 377 697 deaths (2 145 584–2 512 809) in people of all ages, worldwide Streptococcus pneumoniae was the leading cause of lower respiratory infection morbidity and mortality globally, contributing to more deaths than all other aetiologies combined in 2016 (1 189 937 deaths, 95% UI 690 445–1 770 660) Childhood wasting remains the leading risk factor for lower respiratory infection mortality among children younger than 5 years, responsible for 61·4% of lower respiratory infection deaths in 2016 (95% UI 45·7–69·6) Interventions to improve wasting, household air pollution, ambient particulate matter pollution, and expanded antibiotic use could avert one under-5 death due to lower respiratory infection for every 4000 children treated in the countries with the highest lower respiratory infection burden Interpretation Our findings show substantial progress in the reduction of lower respiratory infection burden, but this progress has not been equal across locations, has been driven by decreases in several primary risk factors, and might require more effort among elderly adults By highlighting regions and populations with the highest burden, and the risk factors that could have the greatest effect, funders, policy makers, and programme implementers can more effectively reduce lower respiratory infections among the world's most susceptible populations Funding Bill & Melinda Gates Foundation

1,147 citations



Journal ArticleDOI
Christopher Troeger, Brigette F. Blacker, Ibrahim A Khalil, Puja C Rao, Shujin Cao, Stephanie R. M. Zimsen, Samuel B. Albertson, Jeffery D Stanaway, Aniruddha Deshpande, Zegeye Abebe, Nelson Alvis-Guzman, Azmeraw T. Amare, Solomon Weldegebreal Asgedom, Zelalem Alamrew Anteneh, Carl Abelardo T. Antonio, Olatunde Aremu, Ephrem Tsegay Asfaw, Tesfay Mehari Atey, Suleman Atique, Euripide Frinel G Arthur Avokpaho, Ashish Awasthi, Henok Tadesse Ayele, Aleksandra Barac, Mauricio Lima Barreto, Quique Bassat, Saba Abraham Belay, Isabela M. Benseñor, Zulfiqar A Bhutta, Ali Bijani, Hailemichael Bizuneh, Carlos A Castañeda-Orjuela, Abel Fekadu Dadi, Lalit Dandona, Rakhi Dandona, Huyen Phuc Do, Manisha Dubey, Eleonora Dubljanin, Dumessa Edessa, Aman Yesuf Endries, Babak Eshrati, Tamer H. Farag, Garumma Tolu Feyissa, Kyle J Foreman, Mohammad H. Forouzanfar, Nancy Fullman, Peter W. Gething, Melkamu Dedefo Gishu, William W Godwin, Harish Chander Gugnani, Rashmi Gupta, Gessessew Bugssa Hailu, Hamid Yimam Hassen, Desalegn Tsegaw Hibstu, Olayinka Stephen Ilesanmi, Jost B. Jonas, Amaha Kahsay, Gagandeep Kang, Amir Kasaeian, Yousef Khader, Ejaz Ahmad Khan, Muhammad Ali Khan, Young-Ho Khang, Niranjan Kissoon, Sonali Kochhar, Karen L. Kotloff, Ai Koyanagi, G Anil Kumar, Hassan Magdy Abd El Razek, Reza Malekzadeh, Deborah Carvalho Malta, Suresh Mehata, Walter Mendoza, Desalegn Tadese Mengistu, Bereket Gebremichael Menota, Haftay Berhane Mezgebe, Fitsum Weldegebreal Mlashu, Srinivas Murthy, Gurudatta Naik, Cuong Tat Nguyen, Trang Huyen Nguyen, Dina Nur Anggraini Ningrum, Felix Akpojene Ogbo, Andrew T Olagunju, Deepak Paudel, James A Platts-Mills, Mostafa Qorbani, Anwar Rafay, Rajesh Kumar Rai, Saleem M Rana, Chhabi Lal Ranabhat, Davide Rasella, Sarah E Ray, Cesar Reis, Andre M. N. Renzaho, Mohammad Sadegh Rezai, George Mugambage Ruhago, Saeid Safiri, Joshua A. Salomon, Juan Sanabria, Benn Sartorius, Monika Sawhney, Sadaf G. Sepanlou, Mika Shigematsu, Mekonnen Sisay, Ranjani Somayaji, Chandrashekhar T Sreeramareddy, Bryan L. Sykes, Getachew Redae Taffere, Roman Topor-Madry, Bach Xuan Tran, Kald Beshir Tuem, Kingsley N. Ukwaja, Stein Emil Vollset, Judd L. Walson, Marcia R. Weaver, Kidu Gidey Weldegwergs, Andrea Werdecker, Abdulhalik Workicho, Muluken Azage Yenesew, Biruck Desalegn Yirsaw, Naohiro Yonemoto, Maysaa El Sayed Zaki, Theo Vos, Stephen S Lim, Mohsen Naghavi, Christopher J L Murray, Ali H. Mokdad, Simon I. Hay, Robert Reiner 
TL;DR: Substantial progress has been made globally in reducing the burden of diarrhoeal diseases, driven by decreases in several primary risk factors, however, this reduction has not been equal across locations, and burden among adults older than 70 years requires attention.
Abstract: Summary Background The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 provides an up-to-date analysis of the burden of diarrhoea in 195 countries. This study assesses cases, deaths, and aetiologies in 1990–2016 and assesses how the burden of diarrhoea has changed in people of all ages. Methods We modelled diarrhoea mortality with a Bayesian hierarchical modelling platform that evaluates a wide range of covariates and model types on the basis of vital registration and verbal autopsy data. We modelled diarrhoea incidence with a compartmental meta-regression tool that enforces an association between incidence and prevalence, and relies on scientific literature, population representative surveys, and health-care data. Diarrhoea deaths and episodes were attributed to 13 pathogens by use of a counterfactual population attributable fraction approach. Diarrhoea risk factors are also based on counterfactual estimates of risk exposure and the association between the risk and diarrhoea. Each modelled estimate accounted for uncertainty. Findings In 2016, diarrhoea was the eighth leading cause of death among all ages (1 655 944 deaths, 95% uncertainty interval [UI] 1 244 073–2 366 552) and the fifth leading cause of death among children younger than 5 years (446 000 deaths, 390 894–504 613). Rotavirus was the leading aetiology for diarrhoea mortality among children younger than 5 years (128 515 deaths, 105 138–155 133) and among all ages (228 047 deaths, 183 526–292 737). Childhood wasting (low weight-for-height score), unsafe water, and unsafe sanitation were the leading risk factors for diarrhoea, responsible for 80·4% (95% UI 68·2–85·0), 72·1% (34·0–91·4), and 56·4% (49·3–62·7) of diarrhoea deaths in children younger than 5 years, respectively. Prevention of wasting in 1762 children (95% UI 1521–2170) could avert one death from diarrhoea. Interpretation Substantial progress has been made globally in reducing the burden of diarrhoeal diseases, driven by decreases in several primary risk factors. However, this reduction has not been equal across locations, and burden among adults older than 70 years requires attention. Funding Bill & Melinda Gates Foundation.

787 citations



Journal ArticleDOI
Daniel Dicker1, Grant Nguyen2, Degu Abate, Kalkidan Hassen Abate3  +1155 moreInstitutions (7)
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 as mentioned in this paper was the most recent iteration of the GBD, which used all available data to produce estimates of mortality rates between 1950 and 2017 for 23 age groups.

638 citations


Journal ArticleDOI
TL;DR: The pace of progress achieved between 1990 and 2016 varied, with markedly faster improvements occurring between 2000 and 2016 for many countries in sub-Saharan Africa and southeast Asia, whereas several countries in Latin America and elsewhere saw progress stagnate after experiencing considerable advances in the HAQ Index between1990 and 2000.

Journal ArticleDOI
TL;DR: In 2016, the global lifetime risk of stroke from the age of 25 years onward was approximately 25% among both men and women, and there was geographic variation in the lifetime risk, with the highest risks in East Asia, Central Europe, and Eastern Europe.
Abstract: BACKGROUND The lifetime risk of stroke has been calculated in a limited number of selected populations. We sought to estimate the lifetime risk of stroke at the regional, country, and global level using data from a comprehensive study of the prevalence of major diseases. METHODS We used the Global Burden of Disease (GBD) Study 2016 estimates of stroke incidence and the competing risks of death from any cause other than stroke to calculate the cumulative lifetime risks of first stroke, ischemic stroke, or hemorrhagic stroke among adults 25 years of age or older. Estimates of the lifetime risks in the years 1990 and 2016 were compared. Countries were categorized into quintiles of the sociodemographic index (SDI) used in the GBD Study, and the risks were compared across quintiles. Comparisons were made with the use of point estimates and uncertainty intervals representing the 2.5th and 97.5th percentiles around the estimate. RESULTS The estimated global lifetime risk of stroke from the age of 25 years onward was 24.9% (95% uncertainty interval, 23.5 to 26.2); the risk among men was 24.7% (95% uncertainty interval, 23.3 to 26.0), and the risk among women was 25.1% (95% uncertainty interval, 23.7 to 26.5). The risk of ischemic stroke was 18.3%, and the risk of hemorrhagic stroke was 8.2%. In high-SDI, high-middle-SDI, and low- SDI countries, the estimated lifetime risk of stroke was 23.5%, 31.1% (highest risk), and 13.2% (lowest risk), respectively; the 95% uncertainty intervals did not overlap between these categories. The highest estimated lifetime risks of stroke according to GBD region were in East Asia (38.8%), Central Europe (31.7%), and Eastern Europe (31.6%), and the lowest risk was in eastern sub-Saharan Africa (11.8%). The mean global lifetime risk of stroke increased from 22.8% in 1990 to 24.9% in 2016, a relative increase of 8.9% (95% uncertainty interval, 6.2 to 11.5); the competing risk of death from any cause other than stroke was considered in this calculation. CONCLUSIONS In 2016, the global lifetime risk of stroke from the age of 25 years onward was approximately 25% among both men and women. There was geographic variation in the lifetime risk of stroke, with the highest risks in East Asia, Central Europe, and Eastern Europe.

Journal ArticleDOI
TL;DR: The Global Burden of Disease 2016 study (GBD 2016) estimates sources of early death and disability, which can inform policies to improve health care in Indonesia as mentioned in this paper, where the authors used GBD 2016 results for causespecific deaths, years of life lost, years lived with disability, disability-adjusted life-years (DALYs), life expectancy at birth, healthy life expectancy, and risk factors for 333 causes in Indonesia and in seven comparator countries.

Journal ArticleDOI
TL;DR: Incidence of MM is highly variable among countries but has increased uniformly since 1990, with the largest increase in middle and low-middle SDI countries, and access to effective care is very limited in many countries of low socioeconomic development.
Abstract: Introduction Multiple myeloma (MM) is a plasma cell neoplasm with substantial morbidity and mortality. A comprehensive description of the global burden of MM is needed to help direct health policy, resource allocation, research, and patient care. Objective To describe the burden of MM and the availability of effective therapies for 21 world regions and 195 countries and territories from 1990 to 2016. Design and Setting We report incidence, mortality, and disability-adjusted life-year (DALY) estimates from the Global Burden of Disease 2016 study. Data sources include vital registration system, cancer registry, drug availability, and survey data for stem cell transplant rates. We analyzed the contribution of aging, population growth, and changes in incidence rates to the overall change in incident cases from 1990 to 2016 globally, by sociodemographic index (SDI) and by region. We collected data on approval of lenalidomide and bortezomib worldwide. Main Outcomes and Measures Multiple myeloma mortality; incidence; years lived with disabilities; years of life lost; and DALYs by age, sex, country, and year. Results Worldwide in 2016 there were 138 509 (95% uncertainty interval [UI], 121 000-155 480) incident cases of MM with an age-standardized incidence rate (ASIR) of 2.1 per 100 000 persons (95% UI, 1.8-2.3). Incident cases from 1990 to 2016 increased by 126% globally and by 106% to 192% for all SDI quintiles. The 3 world regions with the highest ASIR of MM were Australasia, North America, and Western Europe. Multiple myeloma caused 2.1 million (95% UI, 1.9-2.3 million) DALYs globally in 2016. Stem cell transplantation is routinely available in higher-income countries but is lacking in sub-Saharan Africa and parts of the Middle East. In 2016, lenalidomide and bortezomib had been approved in 73 and 103 countries, respectively. Conclusions and Relevance Incidence of MM is highly variable among countries but has increased uniformly since 1990, with the largest increase in middle and low-middle SDI countries. Access to effective care is very limited in many countries of low socioeconomic development, particularly in sub-Saharan Africa. Global health policy priorities for MM are to improve diagnostic and treatment capacity in low and middle income countries and to ensure affordability of effective medications for every patient. Research priorities are to elucidate underlying etiological factors explaining the heterogeneity in myeloma incidence.

Journal ArticleDOI
TL;DR: The increase in health loss from diabetes since 1990 in India is the highest among major non-communicable diseases and the relative rate of increase highest in several less developed low ETL states, and policy action is needed urgently to control this potentially explosive public health situation.

Journal ArticleDOI
TL;DR: The increasing prevalence and that of several major risk factors in every part of India, especially the highest increase in the prevalence of ischaemic heart disease in the less developed low ETL states, indicates the need for urgent policy and health system response appropriate for the situation in each state.

Journal ArticleDOI
Rafael Lozano1, Nancy Fullman, Degu Abate2, Solomon M Abay  +1313 moreInstitutions (252)
TL;DR: A global attainment analysis of the feasibility of attaining SDG targets on the basis of past trends and a estimates of health-related SDG index values in countries assessed at the subnational level varied substantially, particularly in China and India, although scores in Japan and the UK were more homogeneous.

Journal ArticleDOI
TL;DR: This work estimated population in 195 locations by single year of age and single calendar year from 1950 to 2017 with standardised and replicable methods and used the cohort-component method of population projection, with inputs of fertility, mortality, population, and migration data.

Journal ArticleDOI
Gregory A. Roth1, Gregory A. Roth2, Catherine O. Johnson1, Kalkidan Hassen Abate3, Foad Abd-Allah4, Muktar Beshir Ahmed3, Khurshid Alam5, Tahiya Alam1, Nelson Alvis-Guzman6, Hossein Ansari, Johan Ärnlöv7, Tesfay Mehari Atey8, Ashish Awasthi9, Tadesse Awoke10, Aleksandra Barac11, Till Bärnighausen12, Neeraj Bedi13, Derrick A Bennett14, Isabela M. Benseñor15, Sibhatu Biadgilign, Carlos A Castañeda-Orjuela, Ferrán Catalá-López16, Kairat Davletov17, Samath D Dharmaratne18, Eric L. Ding12, Manisha Dubey19, Emerito Jose A. Faraon20, Talha Farid21, Maryam S. Farvid12, Valery L. Feigin22, João C. Fernandes23, Joseph Frostad1, Alemseged Aregay Gebru8, Johanna M. Geleijnse24, Philimon Gona25, Max Griswold1, Gessessew Bugssa Hailu8, Graeme J. Hankey5, Hamid Yimam Hassen26, Rasmus Havmoeller7, Simon I. Hay1, Susan R. Heckbert1, Caleb Mackay Salpeter Irvine1, Spencer L. James1, Dube Jara27, Amir Kasaeian28, Abdur Rahman Khan21, Sahil Khera29, Abdullah T Khoja30, Jagdish Khubchandani31, Daniel Kim32, Dhaval Kolte33, Dharmesh Kumar Lal9, Anders Larsson34, Shai Linn35, Paulo A. Lotufo15, Hassan Magdy Abd El Razek36, Mohsen Mazidi37, Toni Meier38, Walter Mendoza39, George A. Mensah40, Atte Meretoja41, Haftay Berhane Mezgebe8, Erkin M. Mirrakhimov42, Shafiu Mohammed43, Andrew E. Moran44, Grant Nguyen1, Minh Nguyen1, Kanyin Liane Ong1, Mayowa O. Owolabi45, Martin A Pletcher1, Farshad Pourmalek46, Caroline A. Purcell1, Mostafa Qorbani, Mahfuzar Rahman47, Rajesh Kumar Rai, Usha Ram19, Marissa B Reitsma1, Andre M. N. Renzaho48, Maria Jesus Rios-Blancas, Saeid Safiri49, Joshua A. Salomon12, Benn Sartorius50, Sadaf G. Sepanlou28, Masood Ali Shaikh, Diego Augusto Santos Silva51, Saverio Stranges52, Rafael Tabarés-Seisdedos16, Niguse Tadele Atnafu53, Jarnail Singh Thakur54, Roman Topor-Madry55, Thomas Truelsen56, E. Murat Tuzcu57, Stefanos Tyrovolas58, Kingsley N. Ukwaja, Tommi Vasankari, Vasiliy Victorovich Vlassov59, Stein Emil Vollset60, Tolassa Wakayo3, Robert G. Weintraub61, Charles D.A. Wolfe62, Abdulhalik Workicho3, Gelin Xu63, Simon Yadgir1, Yuichiro Yano64, Paul S. F. Yip65, Naohiro Yonemoto66, Mustafa Z. Younis67, Chuanhua Yu68, Zoubida Zaidi, Maysaa El Sayed Zaki36, Ben Zipkin1, Ashkan Afshin1, Emmanuela Gakidou1, Stephen S Lim1, Ali H. Mokdad1, Mohsen Naghavi1, Theo Vos1, Christopher J L Murray1 
Institute for Health Metrics and Evaluation1, University of Washington2, Jimma University3, Cairo University4, University of Western Australia5, University of Cartagena6, Karolinska Institutet7, Mekelle University8, Public Health Foundation of India9, University of Gondar10, University of Belgrade11, Harvard University12, Jazan University13, University of Oxford14, University of São Paulo15, University of Valencia16, Kazakh National Medical University17, University of Peradeniya18, International Institute for Population Sciences19, University of the Philippines Manila20, University of Louisville21, Auckland University of Technology22, Catholic University of Portugal23, Wageningen University and Research Centre24, University of Massachusetts Boston25, Mizan–Tepi University26, Debre markos University27, Tehran University of Medical Sciences28, New York Medical College29, Islamic University30, Ball State University31, Northeastern University32, Brown University33, Uppsala University34, University of Haifa35, Mansoura University36, Chinese Academy of Sciences37, Martin Luther University of Halle-Wittenberg38, United Nations Population Fund39, National Institutes of Health40, University of Melbourne41, Kyrgyz State Medical Academy42, Ahmadu Bello University43, Columbia University44, University of Ibadan45, University of British Columbia46, BRAC47, University of Sydney48, University of Maragheh49, University of KwaZulu-Natal50, Universidade Federal de Santa Catarina51, University of Western Ontario52, Addis Ababa University53, Post Graduate Institute of Medical Education and Research54, Jagiellonian University Medical College55, University of Copenhagen56, Cleveland Clinic57, Hospital Sant Joan de Déu Barcelona58, National Research University – Higher School of Economics59, Norwegian Institute of Public Health60, Royal Children's Hospital61, King's College London62, Nanjing University63, University of Mississippi Medical Center64, University of Hong Kong65, Kyoto University66, Jackson State University67, Wuhan University68
TL;DR: Large disparities in total burden of CVD persist between US states despite marked improvements in CVD burden, and increases in risk-deleted CVD DALY rates between 2006 and 2016 in 16 states suggest additional unmeasured risks beyond these traditional factors.
Abstract: Importance Cardiovascular disease (CVD) is the leading cause of death in the United States, but regional variation within the United States is large. Comparable and consistent state-level measures of total CVD burden and risk factors have not been produced previously. Objective To quantify and describe levels and trends of lost health due to CVD within the United States from 1990 to 2016 as well as risk factors driving these changes. Design, Setting, and Participants Using the Global Burden of Disease methodology, cardiovascular disease mortality, nonfatal health outcomes, and associated risk factors were analyzed by age group, sex, and year from 1990 to 2016 for all residents in the United States using standardized approaches for data processing and statistical modeling. Burden of disease was estimated for 10 groupings of CVD, and comparative risk analysis was performed. Data were analyzed from August 2016 to July 2017. Exposures Residing in the United States. Main Outcomes and Measures Cardiovascular disease disability-adjusted life-years (DALYs). Results Between 1990 and 2016, age-standardized CVD DALYs for all states decreased. Several states had large rises in their relative rank ordering for total CVD DALYs among states, including Arkansas, Oklahoma, Alabama, Kentucky, Missouri, Indiana, Kansas, Alaska, and Iowa. The rate of decline varied widely across states, and CVD burden increased for a small number of states in the most recent years. Cardiovascular disease DALYs remained twice as large among men compared with women. Ischemic heart disease was the leading cause of CVD DALYs in all states, but the second most common varied by state. Trends were driven by 12 groups of risk factors, with the largest attributable CVD burden due to dietary risk exposures followed by high systolic blood pressure, high body mass index, high total cholesterol level, high fasting plasma glucose level, tobacco smoking, and low levels of physical activity. Increases in risk-deleted CVD DALY rates between 2006 and 2016 in 16 states suggest additional unmeasured risks beyond these traditional factors. Conclusions and Relevance Large disparities in total burden of CVD persist between US states despite marked improvements in CVD burden. Differences in CVD burden are largely attributable to modifiable risk exposures.

Journal ArticleDOI
Fatima Marinho, Valéria Maria de Azeredo Passos, Deborah Carvalho Malta, Elizabeth Barboza França, Daisy M X Abreu, Valdelaine Etelvina Miranda de Araújo, Maria Teresa Bustamante-Teixeira, Paulo Augusto Moreira Camargos, Carolina Cândida da Cunha, Bruce Bartholow Duncan, Mariana Santos Felisbino-Mendes, Maximiliano Ribeiro Guerra, Mark Drew Crosland Guimarães, Paulo A. Lotufo, Wagner Marcenes, Patrícia Oliveira, Marcel de Moares Pedroso, Antonio Luiz Pinho Ribeiro, Maria Inês Schmidt, Renato Azeredo Teixeira, Ana Maria Nogales Vasconcelos, Mauricio Lima Barreto, Isabela M. Benseñor, Luisa Campos Caldeira Brant, Rafael Moreira Claro, Alexandre C. Pereira, Ewerton Cousin, Maria Paula Curado, Kadine Priscila Bender dos Santos, André Faro, Cleusa P. Ferri, João M. Furtado, Julia Gall, Scott D Glenn, Alessandra C. Goulart, Lenice Harumi Ishitani, Christian Kieling, Roberto Marini Ladeira, Ísis Eloah Machado, Sheila Cristina Ouriques Martins, Francisco Rogerlândio Martins-Melo, Ana Paula Souto Melo, Molly K. Miller-Petrie, Meghan D. Mooney, Bruno Pereira Nunes, Marcos Roberto Tovani Palone, Claudia Cristina de Aguiar Pereira, Davide Rasella, Sarah E Ray, Leonardo Roever, Raphael de Freitas Saldanha, Itamar S. Santos, Ione Jayce Ceola Schneider, Diego Augusto Santos Silva, Dayane Gabriele Alves Silveira, Adauto Martins Soares Filho, Tatiane Cristina Moraes Sousa, Célia Landmann Szwarcwald, Jefferson Traebert, Gustavo Velasquez-Melendez, Yuan-Pang Wang, Rafael Lozano, Christopher J L Murray, Mohsen Naghavi 
TL;DR: An epidemiological transition towards non-communicable diseases and related risks occurred nationally, but later in some states, while interpersonal violence grew as a health concern and policy makers can use these results to address health disparities.

Journal ArticleDOI
TL;DR: The substantial heterogeneity in the state-level incidence rate and health loss trends of the different types of cancer in India over this 26-year period should be taken into account to strengthen infrastructure and human resources for cancer prevention and control at both the national and state levels.
Abstract: Summary Background Previous efforts to report estimates of cancer incidence and mortality in India and its different parts include the National Cancer Registry Programme Reports, Sample Registration System cause of death findings, Cancer Incidence in Five Continents Series, and GLOBOCAN We present a comprehensive picture of the patterns and time trends of the burden of total cancer and specific cancer types in each state of India estimated as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 because such a systematic compilation is not readily available Methods We used all accessible data from multiple sources, including 42 population-based cancer registries and the nationwide Sample Registration System of India, to estimate the incidence of 28 types of cancer in every state of India from 1990 to 2016 and the deaths and disability-adjusted life-years (DALYs) caused by them, as part of GBD 2016 We present incidence, DALYs, and death rates for all cancers together, and the trends of all types of cancers, highlighting the heterogeneity in the burden of specific types of cancers across the states of India We also present the contribution of major risk factors to cancer DALYs in India Findings 8·3% (95% uncertainty interval [UI] 7·9–8·6) of the total deaths and 5·0% (4·6–5·5) of the total DALYs in India in 2016 were due to cancer, which was double the contribution of cancer in 1990 However, the age-standardised incidence rate of cancer did not change substantially during this period The age-standardised cancer DALY rate had a 2·6 times variation across the states of India in 2016 The ten cancers responsible for the highest proportion of cancer DALYs in India in 2016 were stomach (9·0% of the total cancer DALYs), breast (8·2%), lung (7·5%), lip and oral cavity (7·2%), pharynx other than nasopharynx (6·8%), colon and rectum (5·8%), leukaemia (5·2%), cervical (5·2%), oesophageal (4·3%), and brain and nervous system (3·5%) cancer Among these cancers, the age-standardised incidence rate of breast cancer increased significantly by 40·7% (95% UI 7·0–85·6) from 1990 to 2016, whereas it decreased for stomach (39·7%; 34·3–44·0), lip and oral cavity (6·4%; 0·4–18·6), cervical (39·7%; 26·5–57·3), and oesophageal cancer (31·2%; 27·9–34·9), and leukaemia (16·1%; 4·3–24·2) We found substantial inter-state heterogeneity in the age-standardised incidence rate of the different types of cancers in 2016, with a 3·3 times to 11·6 times variation for the four most frequent cancers (lip and oral, breast, lung, and stomach) Tobacco use was the leading risk factor for cancers in India to which the highest proportion (10·9%) of cancer DALYs could be attributed in 2016 Interpretation The substantial heterogeneity in the state-level incidence rate and health loss trends of the different types of cancer in India over this 26-year period should be taken into account to strengthen infrastructure and human resources for cancer prevention and control at both the national and state levels These efforts should focus on the ten cancers contributing the highest DALYs in India, including cancers of the stomach, lung, pharynx other than nasopharynx, colon and rectum, leukaemia, oesophageal, and brain and nervous system, in addition to breast, lip and oral cavity, and cervical cancer, which are currently the focus of screening and early detection programmes Funding Bill & Melinda Gates Foundation; and Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare, Government of India


Journal ArticleDOI
28 Aug 2018-JAMA
TL;DR: Between 195 000 and 276 000 firearm injury deaths globally in 2016 were estimated, the majority of which were firearm homicides, and there was variation among countries and across demographic subgroups.
Abstract: Importance Understanding global variation in firearm mortality rates could guide prevention policies and interventions. Objective To estimate mortality due to firearm injury deaths from 1990 to 2016 in 195 countries and territories. Design, Setting, and Participants This study used deidentified aggregated data including 13 812 location-years of vital registration data to generate estimates of levels and rates of death by age-sex-year-location. The proportion of suicides in which a firearm was the lethal means was combined with an estimate of per capita gun ownership in a revised proxy measure used to evaluate the relationship between availability or access to firearms and firearm injury deaths. Exposures Firearm ownership and access. Main Outcomes and Measures Cause-specific deaths by age, sex, location, and year. Results Worldwide, it was estimated that 251 000 (95% uncertainty interval [UI], 195 000-276 000) people died from firearm injuries in 2016, with 6 countries (Brazil, United States, Mexico, Colombia, Venezuela, and Guatemala) accounting for 50.5% (95% UI, 42.2%-54.8%) of those deaths. In 1990, there were an estimated 209 000 (95% UI, 172 000 to 235 000) deaths from firearm injuries. Globally, the majority of firearm injury deaths in 2016 were homicides (64.0% [95% UI, 54.2%-68.0%]; absolute value, 161 000 deaths [95% UI, 107 000-182 000]); additionally, 27% were firearm suicide deaths (67 500 [95% UI, 55 400-84 100]) and 9% were unintentional firearm deaths (23 000 [95% UI, 18 200-24 800]). From 1990 to 2016, there was no significant decrease in the estimated global age-standardized firearm homicide rate (−0.2% [95% UI, −0.8% to 0.2%]). Firearm suicide rates decreased globally at an annualized rate of 1.6% (95% UI, 1.1-2.0), but in 124 of 195 countries and territories included in this study, these levels were either constant or significant increases were estimated. There was an annualized decrease of 0.9% (95% UI, 0.5%-1.3%) in the global rate of age-standardized firearm deaths from 1990 to 2016. Aggregate firearm injury deaths in 2016 were highest among persons aged 20 to 24 years (for men, an estimated 34 700 deaths [95% UI, 24 900-39 700] and for women, an estimated 3580 deaths [95% UI, 2810-4210]). Estimates of the number of firearms by country were associated with higher rates of firearm suicide ( P R2 = 0.21) and homicide ( P R2 = 0.35). Conclusions and Relevance This study estimated between 195 000 and 276 000 firearm injury deaths globally in 2016, the majority of which were firearm homicides. Despite an overall decrease in rates of firearm injury death since 1990, there was variation among countries and across demographic subgroups.

Journal ArticleDOI
TL;DR: Life expectancy and YLLs have improved more slowly since 2010 in all UK countries compared with 1990–2010, and targeted actions are needed if the rate of improvement is to recover.

Journal ArticleDOI
TL;DR: If current trends in tuberculosis incidence continue, few countries are likely to meet the SDG target to end the tuberculosis epidemic by 2030, and several regions had higher rates of age-standardised incidence and mortality than expected on the basis of their SDI levels in 2016.
Abstract: Summary Background Although a preventable and treatable disease, tuberculosis causes more than a million deaths each year. As countries work towards achieving the Sustainable Development Goal (SDG) target to end the tuberculosis epidemic by 2030, robust assessments of the levels and trends of the burden of tuberculosis are crucial to inform policy and programme decision making. We assessed the levels and trends in the fatal and non-fatal burden of tuberculosis by drug resistance and HIV status for 195 countries and territories from 1990 to 2016. Methods We analysed 15 943 site-years of vital registration data, 1710 site-years of verbal autopsy data, 764 site-years of sample-based vital registration data, and 361 site-years of mortality surveillance data to estimate mortality due to tuberculosis using the Cause of Death Ensemble model. We analysed all available data sources, including annual case notifications, prevalence surveys, population-based tuberculin surveys, and estimated tuberculosis cause-specific mortality to generate internally consistent estimates of incidence, prevalence, and mortality using DisMod-MR 2.1, a Bayesian meta-regression tool. We assessed how the burden of tuberculosis differed from the burden predicted by the Socio-demographic Index (SDI), a composite indicator of income per capita, average years of schooling, and total fertility rate. Findings Globally in 2016, among HIV-negative individuals, the number of incident cases of tuberculosis was 9·02 million (95% uncertainty interval [UI] 8·05–10·16) and the number of tuberculosis deaths was 1·21 million (1·16–1·27). Among HIV-positive individuals, the number of incident cases was 1·40 million (1·01–1·89) and the number of tuberculosis deaths was 0·24 million (0·16–0·31). Globally, among HIV-negative individuals the age-standardised incidence of tuberculosis decreased annually at a slower rate (–1·3% [–1·5 to −1·2]) than mortality did (–4·5% [–5·0 to −4·1]) from 2006 to 2016. Among HIV-positive individuals during the same period, the rate of change in annualised age-standardised incidence was −4·0% (–4·5 to −3·7) and mortality was −8·9% (–9·5 to −8·4). Several regions had higher rates of age-standardised incidence and mortality than expected on the basis of their SDI levels in 2016. For drug-susceptible tuberculosis, the highest observed-to-expected ratios were in southern sub-Saharan Africa (13·7 for incidence and 14·9 for mortality), and the lowest ratios were in high-income North America (0·4 for incidence) and Oceania (0·3 for mortality). For multidrug-resistant tuberculosis, eastern Europe had the highest observed-to-expected ratios (67·3 for incidence and 73·0 for mortality), and high-income North America had the lowest ratios (0·4 for incidence and 0·5 for mortality). Interpretation If current trends in tuberculosis incidence continue, few countries are likely to meet the SDG target to end the tuberculosis epidemic by 2030. Progress needs to be accelerated by improving the quality of and access to tuberculosis diagnosis and care, by developing new tools, scaling up interventions to prevent risk factors for tuberculosis, and integrating control programmes for tuberculosis and HIV. Funding Bill & Melinda Gates Foundation.

Journal ArticleDOI
Joseph L Dieleman, Nafis Sadat, Angela Y Chang, Nancy Fullman, Cristiana Abbafati, Pawan Acharya, Arsène Kouablan Adou, Aliasghar Ahmad Kiadaliri, Khurshid Alam, Reza Alizadeh-Navaei, Ala'a Alkerwi, Walid Ammar, Carl Abelardo T. Antonio, Olatunde Aremu, Solomon Weldegebreal Asgedom, Tesfay Mehari Atey, Leticia Avila-Burgos, Rakesh Ayer, Hamid Badali, Maciej Banach, Amrit Banstola, Aleksandra Barac, Abate Bekele Belachew, Charles Birungi, Nicola Luigi Bragazzi, Nicholas J K Breitborde, Lucero Cahuana-Hurtado, Josip Car, Ferrán Catalá-López, Abigail Chapin, Catherine S Chen, Lalit Dandona, Rakhi Dandona, Ahmad Daryani, Samath D Dharmaratne, Manisha Dubey, Dumessa Edessa, Erika Eldrenkamp, Babak Eshrati, André Faro, Andrea B. Feigl, Ama Pokuaa Fenny, Florian Fischer, Nataliya Foigt, Kyle J Foreman, Mamata Ghimire, Srinivas Goli, Alemayehu Hailu, Samer Hamidi, Hilda L Harb, Simon I. Hay, Delia Hendrie, Gloria Ikilezi, Mehdi Javanbakht, Denny John, Jost B. Jonas, Alexander S Kaldjian, Amir Kasaeian, Yawukal chane Kasahun, Ibrahim A Khalil, Young-Ho Khang, Jagdish Khubchandani, Yun Jin Kim, Jonas Minet Kinge, Soewarta Kosen, Kristopher J Krohn, G Anil Kumar, Alessandra Lafranconi, Hilton Lam, Stefan Listl, Hassan Magdy Abd El Razek, Mohammed Magdy Abd El Razek, Azeem Majeed, Reza Malekzadeh, Deborah Carvalho Malta, German Martinez, George A. Mensah, Atte Meretoja, Angela E Micah, Ted R. Miller, Erkin M. Mirrakhimov, Fitsum Weldegebreal Mlashu, Ebrahim Mohammed, Shafiu Mohammed, Mark Moses, Seyyed Meysam Mousavi, Mohsen Naghavi, Vinay Nangia, Frida Namnyak Ngalesoni, Cuong Tat Nguyen, Trang Huyen Nguyen, Yirga Niriayo, Mehdi Noroozi, Mayowa O. Owolabi, Tejas Patel, David M. Pereira, Suzanne Polinder, Mostafa Qorbani, Anwar Rafay, Alireza Rafiei, Vafa Rahimi-Movaghar, Rajesh Kumar Rai, Usha Ram, Chhabi Lal Ranabhat, Sarah E Ray, Robert Reiner, Haniye Sadat Sajadi, Rocco Santoro, João Vasco Santos, Abdur Razzaque Sarker, Benn Sartorius, Maheswar Satpathy, Sadaf G. Sepanlou, Masood Ali Shaikh, Mehdi Sharif, Jun She, Aziz Sheikh, Mark G. Shrime, Mekonnen Sisay, Samir Soneji, Moslem Soofi, Reed J D Sorensen, Henok Tadesse, Tianchan Tao, Tara Templin, Azeb Gebresilassie Tesema, Subash Thapa, Ruoyan Tobe-Gai, Roman Topor-Madry, Bach Xuan Tran, Khanh Bao Tran, Tung Thanh Tran, Eduardo A. Undurraga, Tommi Vasankari, Francesco Saverio Violante, Andrea Werdecker, Tissa Wijeratne, Gelin Xu, Naohiro Yonemoto, Mustafa Z. Younis, Chuanhua Yu, Maysaa El Sayed Zaki, Bianca S. Zlavog, Christopher J L Murray 
TL;DR: In this paper, the authors used historical data on gross domestic product (GDP) and health spending for 188 countries from 1995 to 2015, and projected annual GDP, development assistance for health, and government, out-of-pocket, and prepaid private health spending from 2015 through to 2040 as a reference scenario.

Journal ArticleDOI
Joseph L Dieleman, Annie Haakenstad, Angela E Micah, Mark Moses, Cristiana Abbafati, Pawan Acharya, Tara Ballav Adhikari, Arsène Kouablan Adou, Aliasghar Ahmad Kiadaliri, Khurshid Alam, Reza Alizadeh-Navaei, Ala'a Alkerwi, Walid Ammar, Carl Abelardo T. Antonio, Olatunde Aremu, Solomon Weldegebreal Asgedom, Tesfay Mehari Atey, Leticia Avila-Burgos, Ashish Awasthi, Rakesh Ayer, Hamid Badali, Maciej Banach, Amrit Banstola, Aleksandra Barac, Abate Bekele Belachew, Charles Birungi, Nicola Luigi Bragazzi, Nicholas J K Breitborde, Lucero Cahuana-Hurtado, Josip Car, Ferrán Catalá-López, Abigail Chapin, Lalit Dandona, Rakhi Dandona, Ahmad Daryani, Samath D Dharmaratne, Manisha Dubey, Dumessa Edessa, Erika Eldrenkamp, Babak Eshrati, André Faro, Andrea B. Feigl, Ama Pokuaa Fenny, Florian Fischer, Nataliya Foigt, Kyle J Foreman, Nancy Fullman, Mamata Ghimire, Srinivas Goli, Alemayehu Hailu, Samer Hamidi, Hilda L Harb, Simon I. Hay, Delia Hendrie, Gloria Ikilezi, Mehdi Javanbakht, Denny John, Jost B. Jonas, Alexander S Kaldjian, Amir Kasaeian, Jennifer Kates, Ibrahim A Khalil, Young-Ho Khang, Jagdish Khubchandani, Yun Jin Kim, Jonas Minet Kinge, Soewarta Kosen, Kristopher J Krohn, G Anil Kumar, Hilton Lam, Stefan Listl, Hassan Magdy Abd El Razek, Mohammed Magdy Abd El Razek, Azeem Majeed, Reza Malekzadeh, Deborah Carvalho Malta, George A. Mensah, Atte Meretoja, Ted R. Miller, Erkin M. Mirrakhimov, Fitsum Weldegebreal Mlashu, Ebrahim Mohammed, Shafiu Mohammed, Mohsen Naghavi, Vinay Nangia, Frida Namnyak Ngalesoni, Cuong Tat Nguyen, Trang Huyen Nguyen, Yirga Niriayo, Mehdi Noroozi, Mayowa O. Owolabi, David M. Pereira, Mostafa Qorbani, Anwar Rafay, Alireza Rafiei, Vafa Rahimi-Movaghar, Rajesh Kumar Rai, Usha Ram, Chhabi Lal Ranabhat, Sarah E Ray, Robert Reiner, Nafis Sadat, Haniye Sadat Sajadi, João Vasco Santos, Abdur Razzaque Sarker, Benn Sartorius, Maheswar Satpathy, Miloje Savic, Matthew T. Schneider, Sadaf G. Sepanlou, Masood Ali Shaikh, Mehdi Sharif, Jun She, Aziz Sheikh, Mekonnen Sisay, Samir Soneji, Moslem Soofi, Henok Tadesse, Tianchan Tao, Tara Templin, Azeb Gebresilassie Tesema, Subash Thapa, Alan J Thomson, Ruoyan Tobe-Gai, Roman Topor-Madry, Bach Xuan Tran, Khanh Bao Tran, Tung Thanh Tran, Eduardo A. Undurraga, Tommi Vasankari, Francesco Saverio Violante, Tissa Wijeratne, Gelin Xu, Naohiro Yonemoto, Mustafa Z. Younis, Chuanhua Yu, Maysaa El Sayed Zaki, Lei Zhou, Bianca S. Zlavog, Christopher J L Murray 
TL;DR: In this article, the authors developed improved estimates of health spending by source, including development assistance for health, and for the first time, estimated HIV/AIDS spending on prevention and treatment and by source of funding, for 188 countries.

Journal ArticleDOI
TL;DR: India's proportional contribution to global suicide deaths is high and increasing, and SDR in India is higher than expected for its Socio-Demographic Index level, especially for women, with substantial variations in the magnitude and men-to-women ratio between the states.
Abstract: Summary Background A systematic understanding of suicide mortality trends over time at the subnational level for India's 1·3 billion people, 18% of the global population, is not readily available. Thus, we aimed to report time trends of suicide deaths, and the heterogeneity in its distribution between the states of India from 1990 to 2016. Methods As part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016, we estimated suicide death rates (SDRs) for both sexes in each state of India from 1990 to 2016. We used various data sources for estimating cause-specific mortality in India. For suicide mortality in India before 2000, estimates were based largely on GBD covariates. For each state, we calculated the ratio of the observed SDR to the rate expected in geographies globally with similar GBD Socio-demographic Index in 2016 (ie, the observed-to-expected ratio); and assessed the age distribution of suicide deaths, and the men-to-women ratio of SDR over time. Finally, we assessed the probability for India and the states of reaching the Sustainable Development Goal (SDG) target of a one-third reduction in SDR from 2015 to 2030, using location-wise trends of the age-standardised SDR from 1990 to 2016. We calculated 95% uncertainty intervals (UIs) for the point estimates. Findings There were 230 314 (95% UI 194 058–250 260) suicide deaths in India in 2016. India's contribution to global suicide deaths increased from 25·3% in 1990 to 36·6% in 2016 among women, and from 18·7% to 24·3% among men. Age-standardised SDR among women in India reduced by 26·7% from 20·0 (95% UI 16·5–23·5) in 1990 to 14·7 (13·1–16·2) per 100 000 in 2016, but the age-standardised SDR among men was the same in 1990 (22·3 [95% UI 14·4–27·4] per 100 000) and 2016 (21·2 [14·6–23·6] per 100 000). SDR in women was 2·1 times higher in India than the global average in 2016, and the observed-to-expected ratio was 2·74, ranging from 0·45 to 4·54 between the states. SDR in men was 1·4 times higher in India than the global average in 2016, with an observed-to-expected ratio of 1·31, ranging from 0·40 to 2·42 between the states. There was a ten-fold variation between the states in the SDR for women and six-fold variation for men in 2016. The men-to-women ratio of SDR for India was 1·34 in 2016, ranging from 0·97 to 4·11 between the states. The highest age-specific SDRs among women in 2016 were for ages 15–29 years and 75 years or older, and among men for ages 75 years or older. Suicide was the leading cause of death in India in 2016 for those aged 15–39 years; 71·2% of the suicide deaths among women and 57·7% among men were in this age group. If the trends observed up to 2016 continue, the probability of India achieving the SDG SDR reduction target in 2030 is zero, and the majority of the states with 81·3% of India's population have less than 10% probability, three states have a probability of 10·3–15·0%, and six have a probability of 25·1–36·7%. Interpretation India's proportional contribution to global suicide deaths is high and increasing. SDR in India is higher than expected for its Socio-Demographic Index level, especially for women, with substantial variations in the magnitude and men-to-women ratio between the states. India must develop a suicide prevention strategy that takes into account these variations in order to address this major public health problem. Funding Bill & Melinda Gates Foundation; and Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare, Government of India.

Journal ArticleDOI
TL;DR: La mortalidad, los anos de vida ajustados por discapacidad (AVAD), los factores de riesgo y el progreso hacia los objetivos de desarrollo sostenible (ODS) a partir of los datos de GBD 2016 en Espana are presented.
Abstract: Resumen Antecedentes y objetivo El estudio de la carga global de las enfermedades, conocido como GBD por sus siglas en ingles (global burden of disease), mide la salud poblacional en todo el mundo de forma anual y sus resultados estan disponibles por pais. Utilizamos las estimaciones GBD para resumir el estado de salud poblacional en Espana en 2016 y describir las tendencias en morbimortalidad de 1990 a 2016. Material y metodos GBD 2016 estima la carga debida a 333 enfermedades y lesiones, y a 84 factores de riesgo. La lista de causas de GBD es jerarquica e incluye 3 categorias de nivel superior: 1) enfermedades transmisibles, maternas, neonatales y nutricionales; 2) enfermedades no transmisibles (ENT), y 3) accidentes. Se presentan la mortalidad, los anos de vida ajustados por discapacidad (AVAD), los factores de riesgo y el progreso hacia los objetivos de desarrollo sostenible (ODS) a partir de los datos de GBD 2016 en Espana. Resultados En 2016 en Espana hubo 418.516 muertes, de una poblacion total de 46,5 millones, y el 80,5% de ellas ocurrieron en personas de 70 anos o mas. Las ENT fueron la principal causa de muerte (92,8%), con 388.617 (intervalo de incertidumbre del 95% 374.959-402.486), seguidas de los accidentes (3,6%), con 15.052 (13.902-17.107), y de las enfermedades transmisibles (3,5%), con 14.847 (13.208-16.482) muertes. Las 5 principales causas especificas de muerte fueron la cardiopatia isquemica (CI), con el 14,6% de todas las muertes, la enfermedad de Alzheimer y otras demencias (13,6%), el accidente cerebrovascular (7,1%), la enfermedad pulmonar obstructiva cronica (6,9%) y el cancer de pulmon (5,0%). Se observaron incrementos notables en la mortalidad de 1990 a 2016 en otros canceres, infecciones respiratorias del tracto inferior, enfermedad renal cronica y otras enfermedades cardiovasculares, entre otros. Por el contrario, los accidentes de trafico bajaron del puesto 8 al 32 y la diabetes del 6 al 10. Los dolores de espalda y cervicales se convirtieron en la causa principal de AVAD en Espana en 2016, superando a la CI, mientras que la enfermedad de Alzheimer paso del puesto 9 al 3. Los mayores cambios en AVAD se observaron para accidentes de trafico, que cayeron de la posicion 4 a la posicion 16, y los trastornos congenitos, de la 17 a la 35; por el contrario, los trastornos orales aumentaron, pasando del puesto 25 al 17. En general, fumar es, con mucho, el factor de riesgo mas relevante en Espana, seguido de presion arterial alta, indice de masa corporal alto, consumo de alcohol y glucemia alta en ayunas. Finalmente, Espana obtuvo 74,3 sobre 100 puntos en la clasificacion del indice ODS en 2016, y los principales determinantes de salud nacionales relacionados con los ODS fueron el consumo de alcohol, el tabaquismo y la obesidad infantil. Se proyecta un aumento a 80,3 puntos en 2030. Conclusion Los dolores de espalda y cervical fueron el contribuyente mas importante de discapacidad en Espana en 2016. Hubo un aumento notable de la carga poblacional debida a la enfermedad de Alzheimer y otras demencias. El tabaco sigue siendo el riesgo para la salud mas importante que debe abordarse en Espana.

Journal ArticleDOI
27 Mar 2018-JAMA
TL;DR: There were declines in mortality from most categories of infectious diseases, with large differences among US counties, and Mortality from meningitis and tuberculosis decreased over the study period in all US counties.
Abstract: Importance Infectious diseases are mostly preventable but still pose a public health threat in the United States, where estimates of infectious diseases mortality are not available at the county level. Objective To estimate age-standardized mortality rates and trends by county from 1980 to 2014 from lower respiratory infections, diarrheal diseases, HIV/AIDS, meningitis, hepatitis, and tuberculosis. Design and Setting This study used deidentified death records from the National Center for Health Statistics (NCHS) and population counts from the US Census Bureau, NCHS, and the Human Mortality Database. Validated small-area estimation models were applied to these data to estimate county-level infectious disease mortality rates. Exposures County of residence. Main Outcomes and Measures Age-standardized mortality rates of lower respiratory infections, diarrheal diseases, HIV/AIDS, meningitis, hepatitis, and tuberculosis by county, year, and sex. Results Between 1980 and 2014, there were 4 081 546 deaths due to infectious diseases recorded in the United States. In 2014, a total of 113 650 (95% uncertainty interval [UI], 108 764-117 942) deaths or a rate of 34.10 (95% UI, 32.63-35.38) deaths per 100 000 persons were due to infectious diseases in the United States compared to a total of 72 220 (95% UI, 69 887-74 712) deaths or a rate of 41.95 (95% UI, 40.52-43.42) deaths per 100 000 persons in 1980, an overall decrease of 18.73% (95% UI, 14.95%-23.33%). Lower respiratory infections were the leading cause of infectious diseases mortality in 2014 accounting for 26.87 (95% UI, 25.79-28.05) deaths per 100 000 persons (78.80% of total infectious diseases deaths). There were substantial differences among counties in death rates from all infectious diseases. Lower respiratory infection had the largest absolute mortality inequality among counties (difference between the 10th and 90th percentile of the distribution, 24.5 deaths per 100 000 persons). However, HIV/AIDS had the highest relative mortality inequality between counties (10.0 as the ratio of mortality rate in the 90th and 10th percentile of the distribution). Mortality from meningitis and tuberculosis decreased over the study period in all US counties. However, diarrheal diseases were the only cause of infectious diseases mortality to increase from 2000 to 2014, reaching a rate of 2.41 (95% UI, 0.86-2.67) deaths per 100 000 persons, with many counties of high mortality extending from Missouri to the northeastern region of the United States. Conclusions and Relevance Between 1980 and 2014, there were declines in mortality from most categories of infectious diseases, with large differences among US counties. However, over this time there was an increase in mortality for diarrheal diseases.